Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR

[1] Wong TY(2008)The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 116-126

[2] Chakravarthy U(2004)Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 477-485

[3] Klein R(2010)Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30 1333-1349

[4] Mitchell P(1991)Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial Arch Ophthalmol 109 1220-1231

[5] Zlateva G(1996)Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration Arch Ophthalmol 114 400-412

[6] Buggage R(2001)Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2 Am J Ophthalmol 131 541-560

[7] Fahrbach K(2003)Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 Am J Ophthalmol 136 407-418

[8] Probst C(2013)Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 122-129

[9] Sledge I(2016)Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Ophthalmology 123 609-616

[10] Congdon N(1994)Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes Trans Am Ophthalmol Soc 92 91-116

[1] Wong TY(2008)The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 116-126

[2] Chakravarthy U(2004)Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 477-485

[3] Klein R(2010)Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30 1333-1349

[4] Mitchell P(1991)Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial Arch Ophthalmol 109 1220-1231

[5] Zlateva G(1996)Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration Arch Ophthalmol 114 400-412

[6] Buggage R(2001)Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2 Am J Ophthalmol 131 541-560

[7] Fahrbach K(2003)Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 Am J Ophthalmol 136 407-418

[8] Probst C(2013)Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 122-129

[9] Sledge I(2016)Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Ophthalmology 123 609-616

[10] Congdon N(1994)Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes Trans Am Ophthalmol Soc 92 91-116